Pathology Analysis
-
AstraZeneca’s In-House AI Gamble: Accelerating Oncology Research
AstraZeneca is acquiring Modella AI, a pathology analysis firm, to deeply integrate AI into its oncology research and clinical workflows. This move signifies a strategic shift for the pharmaceutical giant, moving from AI as a tool to embedding it into core operations. The acquisition aims to enhance biomarker discovery, refine clinical trial design, and accelerate drug development by bringing AI talent and technology in-house.
